PCDHB13 Inhibitors
PCDHB13 inhibitors are compounds that target the epigenetic regulation mechanisms to modulate the expression of PCDHB13. By inhibiting histone deacetylases (HDACs), these chemicals increase the acetylation of histones, leading to a more relaxed chromatin structure and consequently altering gene expression patterns. This epigenetic remodeling can result in the decreased expression of PCDHB13, as the transcriptional machinery may have reduced access to tightly packed chromatin where the PCDHB13 regulatory elements reside. The overall effect of these HDAC inhibitors is a reduction in the levels of PCDHB13 due to changes in the epigenetic landscape that governs its expression. These changes in the acetylation status of histones can broadly affect many genes, but they are harnessed to specifically target the transcriptional regulation of PCDHB13. The influence on chromatin accessibility and structure by these compounds ultimately leads to the functional inhibition of PCDHB13 as part of a wider shift in transcriptional regulation and chromatin dynamics.
The specific action of these inhibitors disrupts the balance of acetylation and deacetylation on histones, which is a critical determinant in the control of gene expression. The suppression of PCDHB13 through this mechanism is indicative of the broader impact that epigenetic modulation can have on gene regulation. By creating a more open chromatin state, these inhibitors indirectly decrease the expression of PCDHB13, which is thought to be tightly controlled by the epigenetic code. This indirect inhibition approach does not target the protein directly but rather its expression, ensuring that the functional activity of PCDHB13 is diminished due to lower protein levels in the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor leads to hyperacetylation of histones, which can change gene expression patterns, potentially downregulating PCDHB13 by altering chromatin structure and accessibility in the regions where PCDHB13 is regulated. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
As a histone deacetylase inhibitor, this compound modifies the epigenetic regulation of gene expression, possibly decreasing the expression of PCDHB13 by affecting chromatin compaction and gene accessibility. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
This selective histone deacetylase inhibitor can cause changes in gene expression through epigenetic remodeling, which might suppress PCDHB13 transcription as part of a broader shift in gene expression profiles. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
This compound acts as a histone deacetylase inhibitor, potentially altering the transcriptional landscape and reducing PCDHB13 expression through modifications in histone acetylation and chromatin structure. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
By inhibiting histone deacetylases, this compound can disrupt the epigenetic status of genes and potentially downregulate the transcription of PCDHB13 by altering the chromatin environment where its gene regulatory elements are located. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
As an inhibitor of histone deacetylases, it can modulate gene expression patterns, which may include a reduction in PCDHB13 levels due to changes in the epigenetic landscape. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
This broad-spectrum histone deacetylase inhibitor could decrease PCDHB13 expression by inducing hyperacetylation of histones, leading to an open chromatin state that affects gene expression. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
By inhibiting histone deacetylases, this compound is capable of altering gene expression profiles, potentially leading to the downregulation of PCDHB13 transcription through epigenetic modifications. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $61.00 $245.00 $1173.00 | ||
As a histone deacetylase inhibitor, it may affect the expression of PCDHB13 by changing the acetylation status of histones and hence the chromatin structure governing PCDHB13 gene regulation. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $97.00 $525.00 | 1 | |
This histone deacetylase inhibitor can modify chromatin architecture and potentially suppress PCDHB13 expression by altering the accessibility of transcriptional machinery to the gene's regulatory elements. | ||||||